Janssen Sciences Ireland Uc

Janssen Pharmaceutica Nv

Janssen Sciences Ireland Unlimited Company

Janssen R&d Ireland

Anil Koul

David Francis Alain Lançois

Magali Madeleine Simone Motte

Wendy Mia Albert Balemans

Jérôme Emile Georges Guillemont

Koenraad Jozef Lodewijk Marcel Andries

Jerome Emile Guillemont

Jerôme Emile Georges Guillemont

Koenraad Jozef Andries

Eric Pierre Alexandre Arnoult

David Francis Lancois

Jérôme Émile Georges Guillemont

David Francis Alain Lancois

Magali Madeleine Motte

Jerome Emile Georges Guillemont

Ismet Dorange

Elisabeth Therese Pasquier

Dirk André Emmy Roymans

Pierre Jean-Marie Bernard Raboisson

Vadim Bichko

Elisabeth Thérèse Jeanne Pasquier

Antoine Benjamin Michaut

Delphine Yvonne Raymonde Lardeau

Nacer Lounis

Boris Rogovoy

Lieven Meerpoel

Leo Jacobus Jozef Backx

Nele Isa E Goeyvaerts

Maria Cristina Villellas Arilla

Nina Ysebaert

Leo Jacobus Backx

David Craig McGowan

Elisabeth Therese Jeanne Pasquier

David Craig Mc Gowan

Koenraad Jozef Lodewijk Andries

Yvan René Ferdinand Simonnet

Jérome Emile Georges Guillemont

Elisabeth Thérèse Jeanne

Dirk André E Roymans

Steffen Friedrich Walter Weidner

Yvan Rene Ferdinand Simonnet

José Manuel Villalgordo-Soto

David FA Lançois

Leo JJ Backx

Jérôme EG Guillemont

Koenraad JLM Andries

E T J Pasquier

J E G Guillemont

David Francis Alain LANÇOIS

Jérôme ÉMile Georges Guillemont

Wendy Mia Balemans

Dirk Andre Emmy Roymans

Jose Manuel Villalgordo-Soto

Steffen Friedrich Weidner

The present invention relates to novel combinations, which are useful in the treatment of tuberculosis.

PZA and cytochrome Bc1 inhibitor combination treatment

The present invention is directed to the combination of the RSV inhibiting Compound A, i.e. 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one, and the RSV inhibiting Compound B, i.e. (1S,2S)-2-[4-[7-cyclopropyl-5-[(1R)-1-methyl-3,4-dihydro-1H-isoquinoline-2-carbonyl]pyrazolo[1,5-a]pyrimidin-2-yl]-3-fluoro-phenyl]cyclopropanecarboxylic acid for treating or ameliorating RSV infection. The invention further relates to the combination product of Compound A and Compound B, a pharmaceutical product comprising Compound A and Compound B, the use of the combination of Compound A and Compound B&#x2014;or the pharmaceutical product comprising Compound A and Compound B&#x2014;for the treatment of RSV infection, and a method of treating or ameliorating RSV infection in a subject in need thereof comprising administering the combination of Compound A and Compound B in an effective amount to said subject.

Treatment of RSV with combination product

PZA and cytochrome bc1 inhibitor combination treatment

The invention concerns novel substituted pyrazolo- and triazolo-pyrimidine compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection. 

RSV antiviral pyrazolo- and triazolo-pyrimidine compounds

The present invention is related to novel compounds of formula (I) that inhibit the activity of the FabI enzyme which are therefore useful in the treatment of bacterial infections. It further relates to pharmaceutical compositions comprising these compounds, and chemical processes for preparing these compounds. 

Antibacterial cyclopenta[C]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones

The present invention is directed to the combination of the RSV inhibiting Compound A, i.e. 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl) 1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one, and one or more RSV inhibiting Compound B selected from from ribavirin, GS-5806, MDT-637, BTA-9881, BMS-433771, YM-543403, A-60444, TMC-353121, RFI-641, CL-387626, MBX-300, AZ-27, MEDI8897, CR9501, palivizumab, 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-benzimidazol-2-yl}methyl)-1 cyclopropyl-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one, 3-[[7-chloro-3-(2 ethyl-sulfonylethyl)imidazo[1,2-a]pyridin-2-yl]methyl]-1-cyclopropyl-imidazo[4,5-c]pyridin-2 one, N-(2-fluoro-6-methylphenyl)-6-(4-(5-methyl-2-(7-oxa-2-azaspiro[3.5]nonan-2 yl)nicotinamido)benzoyl)-5,6-dihydro-4H-benzo[b]thieno[2,3-d]azepine-2-carboxamide, and 4-amino-8-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-6,6-dimethyl-2-(4-methyl 3-nitrophenyl)-3H-imidazo[4,5-h]isoquinoline-7,9(6H,8H)-dione, for treating or ameliorating RSV infection. The invention further relates to the combination product of Compound A and one or more Compound B, a pharmaceutical product comprising Compound A and one or more Compound B, the use of the combination of Compound A and one or more of Compound B&#x2014;or the pharmaceutical product comprising Compound A and one or more Compound B&#x2014;for the treatment of RSV infection, and a method of treating or ameliorating RSV infection in a subject in need thereof comprising administering the combination of Compound A and one or more Compound B in an effective amount to said subject.

Combination products for the treatment of RSV

Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones

The present invention relates to the following compounds for use in the treatment of a bacterial infection wherein the integers are as defined in the description. The invention also relates to compounds for use as medicaments, pharmaceutical compositions and some novel compounds.

Antibacterial compounds

Antibacterial cyclopenta[C]pyrrole substituted 3,4-Dihydro-1H-[1,8]naphthyridinones

Antibacterial cyclopental[C]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones

Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones

Growing community of inventors

Edegem, Belgium

Anil Koul